Meetings

Conference abstracts

81 public abstracts from 2021 to 2026. Findings are the abstract’s own wording. Level 1 items, where ctDNA or MRD assigned treatment or surveillance, have a coral bar. Slide and poster links, when added, may require an ASCO or ESMO member login.

1 abstracts

Level 2positiveASCO Annual Meeting 2025, Abstract 5502 2025
Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses.
Mayadev J · Abstract 5502 · CALLA (NCT03830866) · Biomarker-evaluable population 185 / 186 / 130 at baseline (C1D1) / C3D1 / 6 months; parent trial 770 randomized
NeXT Personal (Personalis), ultrasensitive tumor-informed MRD assay with up to 1,800 patient-specific variants from WGS
ASCO 2025 abstract 5502 of the CALLA NeXT Personal analysis: baseline ctDNA detection 99%; 6-month detection 23% with durvalumab+CRT vs 36% with CRT; baseline median ctDNA 5,268.2 ppm; PFS HRs for low vs high baseline ctDNA 0.57 (0.26–1.26) with D+CRT and 0.62 (0.31–1.23) with CRT.

Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses.